Carvedilol vs Metoprolol: 7 Key Differences for Heart Failure and Blood Pressure

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

carvedilol vs metoprolol — Carvedilol vs Metoprolol: 7 Key Differences for Heart Failure and Blood Pressure. Read on for an evidence-backed guide covering everything you need to know.

[Key Takeaways box]

Key Takeaways

• Carvedilol showed a 17% lower all-cause mortality than metoprolol tartrate in the landmark COMET trial — the only direct head-to-head comparison in heart failure
• Carvedilol blocks beta-1, beta-2, and alpha-1 receptors, giving it additional vasodilating effects that metoprolol’s selective beta-1 blockade lacks — and this difference has one surprising clinical consequence
• For hypertension alone, both are effective — but one is significantly cheaper and has a once-daily formulation that improves adherence
• The right choice depends on whether you’re treating heart failure, hypertension, or post-heart attack — and a specific comorbidity can flip the recommendation entirely

[Table of Contents]

• What Are Carvedilol and Metoprolol?
• How Do Carvedilol and Metoprolol Work?
• Carvedilol vs Metoprolol: 7 Key Differences
• What Does the Research Say?
• Side Effects & Safety
• Which Beta Blocker Fits Your Situation?
• Dosing and How to Take
• Related Reading
• Frequently Asked Questions
• The Bottom Line

H1: Carvedilol vs Metoprolol: 7 Key Differences for Heart Failure and Blood Pressure

[Quick Answer box] Carvedilol vs metoprolol: the key difference is that carvedilol is a non-selective beta blocker with additional alpha-1 blocking activity (providing vasodilation), while metoprolol is a beta-1 selective blocker. For heart failure, carvedilol has slightly stronger evidence and showed a survival advantage over metoprolol tartrate in the COMET trial. For hypertension alone, metoprolol succinate’s once-daily dosing and lower cost make it a practical first choice for many patients.

Carvedilol vs metoprolol — your doctor mentioned two beta blockers — carvedilol and metoprolol — and asked which you’d prefer. Or maybe you’ve been on one and it’s not working quite right, and a switch is on the table. Either way, you’re facing a decision that seems like it should be simple but isn’t: two drugs, same class, different names. What’s the actual difference?

Here’s the short version: carvedilol vs metoprolol is not just a brand-vs-brand comparison. These two medications work differently at the receptor level, have different clinical trial evidence behind them, and fit different patient profiles. Understanding the 7 key differences below will give you the framework to have an informed conversation with your doctor — and potentially choose the beta blocker that’s a better fit for your specific situation.

H2: What Are Carvedilol and Metoprolol? {#what-are-they}

[Quick Answer box] Both carvedilol (brand name Coreg) and metoprolol (brand names Toprol-XL for succinate, Lopressor for tartrate) are beta blockers — a class of medications that block the effects of adrenaline on the heart, reducing heart rate, blood pressure, and the workload on the heart. They are both FDA-approved for heart failure and hypertension, and both are available as generic medications.

Carvedilol vs metoprolol — carvedilol and metoprolol are two of the most commonly prescribed beta blockers worldwide, but they represent different generations of beta blocker development. Metoprolol, developed in the 1970s, was one of the first “cardioselective” beta blockers — meaning it preferentially blocks beta-1 receptors in the heart while sparing beta-2 receptors in the lungs. Carvedilol, developed later and approved in the 1990s, belongs to the third generation of beta blockers, characterized by additional vasodilating properties through alpha-1 receptor blockade.

Both are available as generic medications, making them accessible and affordable. Metoprolol comes in two formulations that are clinically important to distinguish: metoprolol tartrate (immediate-release, typically taken twice daily) and metoprolol succinate (extended-release, taken once daily). Carvedilol is available as immediate-release (twice daily) and an extended-release formulation (Coreg CR, once daily).

H2: How Do Carvedilol and Metoprolol Work? {#how-they-work}

To understand carvedilol vs metoprolol, you need to understand beta receptors. Think of beta receptors as docking stations on the surface of cells. When adrenaline (epinephrine) docks at a beta-1 receptor in your heart, it signals: “beat faster, squeeze harder.” When it docks at a beta-2 receptor in your lungs, it signals: “open up the airways.” When it docks at an alpha-1 receptor in your blood vessels, it signals: “constrict, raise blood pressure.”

Here’s where carvedilol and metoprolol diverge:

Metoprolol is a selective key that fits only the beta-1 lock. It tells your heart: “ignore that adrenaline.” Heart rate slows, contraction force decreases, and blood pressure drops. But because it largely leaves beta-2 receptors alone, it’s less likely to cause bronchospasm — a critical advantage for patients with asthma or COPD. At higher doses, metoprolol’s selectivity diminishes though, and it starts blocking beta-2 receptors too.

Carvedilol is a master key that fits beta-1, beta-2, AND alpha-1 locks. The beta blockade slows the heart, same as metoprolol. But the alpha-1 blockade adds something extra: it tells blood vessels “relax, don’t constrict” — causing vasodilation that further reduces blood pressure and decreases the resistance the heart pumps against (afterload reduction). This dual mechanism is why carvedilol is sometimes described as a “beta blocker with vasodilator properties.”

[Research Spotlight box] Research Spotlight: Why Alpha-1 Blockade Matters in Heart Failure In heart failure, the body compensates for reduced cardiac output by activating the sympathetic nervous system — flooding the bloodstream with adrenaline and norepinephrine. This constricts blood vessels (via alpha-1 receptors), increasing the workload on an already struggling heart. Carvedilol’s alpha-1 blockade interrupts this vicious cycle, reducing afterload and myocardial oxygen demand simultaneously with its beta-blocking effects. This multi-receptor mechanism is the leading theory for why carvedilol outperformed metoprolol tartrate in the COMET trial. (Source: Poole-Wilson PA et al., Lancet 2003;362:7-13. PMID: 12885765)

H2: Carvedilol vs Metoprolol: 7 Key Differences {#seven-differences}

Here’s where the clinical rubber meets the road. These seven differences in carvedilol vs metoprolol matter for real patients:

1. Receptor Selectivity Carvedilol blocks beta-1, beta-2, and alpha-1 receptors. Metoprolol is selective for beta-1 receptors (at therapeutic doses). This is the foundational difference from which all other differences flow. Carvedilol’s broader blockade means more mechanisms of action but also more potential for side effects like dizziness (from vasodilation) and bronchospasm (from beta-2 blockade).

2. Vasodilation (Blood Vessel Widening) Carvedilol directly dilates blood vessels through alpha-1 blockade, providing an additional blood-pressure-lowering effect beyond heart rate reduction. Metoprolol lowers blood pressure primarily by reducing cardiac output. For patients with both heart failure and hypertension, carvedilol’s dual mechanism can be an advantage.

3. Heart Failure Survival Evidence The COMET trial directly compared carvedilol vs metoprolol (tartrate) in 3,029 patients with chronic heart failure. Carvedilol reduced all-cause mortality by 17% compared to metoprolol tartrate (34% vs 40% at 5 years, hazard ratio 0.83, p=0.0017). This is the strongest piece of evidence favoring carvedilol — but it’s important to note the comparison was against metoprolol tartrate (immediate-release, twice daily), not metoprolol succinate (the once-daily formulation used in the MERIT-HF trial).

4. Effects on Blood Sugar and Lipids Carvedilol has been shown to have neutral or slightly favorable effects on insulin sensitivity and lipid profiles — it doesn’t worsen blood sugar control and may slightly improve it. Metoprolol, like most beta blockers, can increase insulin resistance and raise triglycerides. For patients with diabetes or metabolic syndrome, this difference may influence carvedilol vs metoprolol selection.

5. Dosing Frequency Metoprolol succinate (Toprol-XL) is a true once-daily formulation. Carvedilol immediate-release is typically taken twice daily; the extended-release Coreg CR is once daily but may be more expensive. For patients who struggle with medication adherence, once-daily metoprolol succinate has a practical advantage — missing one dose of a twice-daily drug means 12 hours without coverage, versus 24 hours for a once-daily drug.

6. Respiratory Safety (Asthma/COPD) Metoprolol’s beta-1 selectivity makes it less likely to trigger bronchospasm in patients with reactive airway disease. Carvedilol’s non-selective beta-2 blockade can constrict airways, making it relatively contraindicated in severe asthma. For patients with both hypertension and asthma, metoprolol is generally preferred.

7. Cost and Availability Both are available as inexpensive generics, but metoprolol tartrate is consistently one of the cheapest prescription medications available — often as low as $4 for a 30-day supply through discount programs. Carvedilol is still affordable but typically 2-3 times the cost of generic metoprolol tartrate. For cash-paying patients, this difference matters.

H2: What Does the Research Say? {#what-research-says}

The carvedilol vs metoprolol evidence base spans three decades. Here are the landmark trials:

What this means for you: In carvedilol vs metoprolol for heart failure, the COMET trial gives carvedilol an edge — but only when compared against metoprolol tartrate dosed at 50 mg twice daily, which is not the standard metoprolol succinate regimen used in contemporary practice. Both carvedilol and metoprolol succinate individually reduce heart failure mortality by roughly one-third compared to placebo. For hypertension, they’re comparably effective at lowering blood pressure, with the choice turning more on side effects, cost, and comorbidities.

H2: Side Effects & Safety {#side-effects}

[Who Is This For? / Who Should Avoid It? box] Best suited for: Carvedilol — heart failure with reduced ejection fraction, hypertension with diabetes or metabolic syndrome. Metoprolol — hypertension, post-myocardial infarction, hypertension with asthma/COPD. Caution for: Both — severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, severe peripheral arterial disease. Carvedilol — severe asthma, severe hepatic impairment. Metoprolol — avoid immediate-release tartrate in heart failure (use succinate formulation).

The side effect profiles of carvedilol vs metoprolol reflect their receptor differences:

Drug interactions to know:

• Both carvedilol and metoprolol interact with other heart-rate-slowing drugs (digoxin, amiodarone, verapamil, diltiazem) — combined use can cause dangerous bradycardia
• Carvedilol is metabolized by CYP2D6; metoprolol primarily by CYP2D6 as well — drugs like fluoxetine, paroxetine, and bupropion that inhibit CYP2D6 can increase levels of both
• NSAIDs can blunt the blood-pressure-lowering effect of both
• Neither should be stopped abruptly — rebound tachycardia and hypertension can occur; taper over 1-2 weeks

H2: Which Beta Blocker Fits Your Situation? {#which-fits}

Here’s how the carvedilol vs metoprolol decision maps to real clinical scenarios:

Scenario 1: Heart failure with reduced ejection fraction (HFrEF) Carvedilol is generally preferred (or metoprolol succinate, or bisoprolol — the three “evidence-based” beta blockers in heart failure). Carvedilol’s COMET trial advantage and additional vasodilating effect make it a strong choice. However, if you can’t tolerate carvedilol’s initial dizziness, metoprolol succinate is a proven alternative.

Scenario 2: Post-heart attack (post-MI) Metoprolol has the most direct evidence in post-MI populations, but both are effective. Metoprolol tartrate was studied in the landmark BHAT trial showing 26% mortality reduction post-MI. Carvedilol is also effective post-MI but was studied slightly differently.

Scenario 3: Hypertension with asthma or COPD Metoprolol is preferred due to beta-1 selectivity. Carvedilol’s beta-2 blockade can trigger bronchospasm. For patients with mild COPD and a strong heart failure indication for carvedilol, low-dose carvedilol may still be used cautiously — but metoprolol is the safer default.

Scenario 4: Hypertension with diabetes or metabolic syndrome Carvedilol has an edge due to metabolic neutrality. The GEMINI trial showed carvedilol actually improved insulin sensitivity while metoprolol worsened it. For patients at risk for new-onset diabetes from beta blocker therapy, carvedilol may be the better choice.

Scenario 5: Cost is a major concern Metoprolol tartrate is among the cheapest prescription drugs available. If you’re paying cash, metoprolol tartrate (twice daily) costs roughly $4-10/month versus $10-25/month for carvedilol. The difference is modest but meaningful for patients on multiple medications.

Scenario 6: Difficulty with twice-daily dosing Metoprolol succinate (once daily) has the adherence advantage. If you often forget your evening dose, a once-daily formulation of either drug (metoprolol succinate or carvedilol CR) may improve consistency — but generic metoprolol succinate tends to be cheaper than branded carvedilol CR.

H2: Dosing and How to Take {#dosing}

Carvedilol typical dosing:

• Heart failure: Start at 3.125 mg twice daily; double every 2-4 weeks as tolerated to target 25 mg twice daily (or 50 mg twice daily if >85 kg)
• Hypertension: Start at 6.25 mg twice daily; titrate to 12.5-25 mg twice daily
• Take with food to reduce risk of orthostatic hypotension
• Extended-release (Coreg CR): Start 10 mg once daily; titrate to 20-80 mg once daily

Metoprolol typical dosing:

• Heart failure (succinate): Start at 12.5-25 mg once daily; double every 2 weeks to target 200 mg once daily
• Hypertension (succinate): Start at 25-100 mg once daily; maximum 400 mg/day
• Hypertension (tartrate): Start at 50 mg twice daily; titrate to 100-450 mg/day in divided doses
• Post-MI (tartrate): Start 25-50 mg every 6-12 hours; transition to 100 mg twice daily
• Metoprolol succinate: take once daily, with or without food, at consistent time
• Metoprolol tartrate: take twice daily (morning and evening), with or after meals

Key dosing principles for both:

• “Start low, go slow” — never begin at full dose, particularly in heart failure
• Dose titration should occur every 2-4 weeks — rushing increases side effects
• Do not stop abruptly — taper over 1-2 weeks
• Monitor heart rate and blood pressure during titration; report dizziness, severe fatigue, or heart rate below 50-55 bpm
• If you miss a dose, take it as soon as you remember unless it’s nearly time for the next dose — never double up

For those managing blood pressure or heart failure, browse MedsBase’s Blood Pressure category to ensure consistent medication access.

[Related Reading module]

• Metoprolol Tartrate vs Metoprolol Succinate: 7 Key Differences — If you’re prescribed metoprolol, this distinction is critical
• Bisoprolol vs Metoprolol: Which Beta Blocker Is Right for You? — Another beta blocker comparison with unique evidence in heart failure
• Beta Blockers vs Calcium Channel Blockers: Which Blood Pressure Medication Is Right for You? — Broader class comparison for hypertension treatment

H2: Frequently Asked Questions {#faq}

Q: What is the difference between carvedilol and metoprolol?

A: The key difference in carvedilol vs metoprolol is receptor selectivity. Carvedilol blocks beta-1, beta-2, and alpha-1 receptors, providing both heart rate reduction and blood vessel dilation. Metoprolol is beta-1 selective, primarily reducing heart rate and cardiac output without significant vasodilation. This translates to carvedilol having stronger heart failure evidence (COMET trial), more initial dizziness, and potential metabolic advantages, while metoprolol is safer for asthma/COPD patients and offers a true once-daily succinate formulation.

Q: Is carvedilol better than metoprolol for heart failure?

A: The COMET trial showed carvedilol reduced all-cause mortality by 17% compared to metoprolol tartrate in heart failure patients. However, metoprolol succinate (the once-daily formulation) has its own positive heart failure trial (MERIT-HF, 34% mortality reduction vs placebo). Both are considered first-line evidence-based beta blockers for heart failure with reduced ejection fraction. Carvedilol has a slight evidence edge, but tolerability and individual patient factors often determine the choice.

Q: Which beta blocker is best for heart failure?

A: Three beta blockers have the strongest evidence and guideline endorsement for heart failure: carvedilol, metoprolol succinate, and bisoprolol. These are not interchangeable with other beta blockers (like atenolol or propranolol) that lack heart failure mortality data. Among the three, carvedilol is the only non-selective agent with vasodilating properties. The “best” choice depends on whether you tolerate carvedilol’s initial side effects, your comorbidities (asthma/COPD, diabetes), and dosing preferences.

Q: Can carvedilol and metoprolol be taken together?

A: No. Carvedilol vs metoprolol should not be combined — they belong to the same drug class (beta blockers) and taking both would cause additive bradycardia, hypotension, and heart block risk without additional benefit. Patients are prescribed one or the other. If your doctor switches you from carvedilol to metoprolol (or vice versa), the first drug is stopped (usually tapered) before the second is started.

Q: Which has fewer side effects carvedilol or metoprolol?

A: It depends on which side effect you’re measuring. Carvedilol causes more initial dizziness and hypotension due to alpha-1-mediated vasodilation — particularly after the first few doses. Metoprolol (beta-1 selective) is less likely to cause bronchospasm and may be better tolerated by patients with asthma or COPD. Fatigue and bradycardia are similar between both. For metabolic side effects, carvedilol has a more favorable profile — it doesn’t worsen insulin resistance like metoprolol can.

Q: Does carvedilol lower blood pressure better than metoprolol?

A: Carvedilol and metoprolol lower blood pressure to a similar degree in most studies, but carvedilol achieves this through a dual mechanism (beta blockade + vasodilation), while metoprolol relies primarily on reducing cardiac output. In the GEMINI trial, the blood pressure reduction was comparable. The choice for hypertension is more often guided by tolerability, cost, and comorbidities rather than differences in blood-pressure-lowering efficacy.

Q: Why was carvedilol better than metoprolol in the COMET trial?

A: The COMET trial compared carvedilol 25 mg twice daily against metoprolol tartrate 50 mg twice daily. Several factors may explain carvedilol’s 17% mortality advantage: (1) carvedilol’s additional alpha-1 blockade provides vasodilation that reduces cardiac workload, (2) the metoprolol tartrate dose used in COMET (50 mg BID) may have been suboptimal compared to the doses used in MERIT-HF (metoprolol succinate ~200 mg daily), (3) carvedilol’s broader receptor blockade may provide more complete sympathetic nervous system inhibition. It’s worth noting that metoprolol succinate at guideline-recommended doses has never been directly compared against carvedilol in a large mortality trial.

Q: Is carvedilol or metoprolol better for high blood pressure in diabetics?

A: Carvedilol vs metoprolol for hypertension in diabetics slightly favors carvedilol due to its metabolic profile. The GEMINI trial showed that carvedilol did not worsen insulin sensitivity (and slightly improved it), while metoprolol decreased insulin sensitivity by about 14%. Carvedilol also had neutral effects on triglycerides and HDL cholesterol, while metoprolol modestly increased triglycerides. For diabetic patients requiring a beta blocker, carvedilol’s metabolic neutrality is an advantage — though the long-term clinical significance of this difference (beyond lab values) is less clear.

H2: The Bottom Line {#bottom-line}

Carvedilol vs metoprolol is not a simple “one is better” question. Carvedilol has slightly stronger heart failure evidence (COMET trial) and metabolic advantages that favor it in diabetes, but it causes more initial dizziness and isn’t ideal for asthma patients. Metoprolol offers beta-1 selectivity that’s safer for reactive airway disease, proven post-heart-attack evidence, and a convenient once-daily succinate formulation — all at a lower cost.

The right choice depends on your primary condition (heart failure, hypertension, post-MI), your comorbidities (asthma, diabetes), your tolerance for initial side effects, and practical factors like cost and dosing frequency. Both are effective, both save lives in heart failure, and either is vastly better than taking no beta blocker when one is indicated.

One immediate action: If you’re prescribed carvedilol or metoprolol, ask your doctor: “Which formulation am I getting?” The difference between metoprolol tartrate (twice daily) and metoprolol succinate (once daily) is clinically significant — make sure you know which one you’re taking and why.

What to read next:

• On metoprolol? Understanding the tartrate vs succinate difference could affect your adherence.
• Still comparing options? Our bisoprolol vs metoprolol comparison covers another evidence-based beta blocker for heart failure.
• Wondering about a different class entirely? Read our beta blockers vs calcium channel blockers guide for a broader treatment framework.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change the dose of carvedilol, metoprolol, or any beta blocker without consulting your healthcare provider. Abrupt discontinuation of beta blockers can cause rebound hypertension, tachycardia, and — in patients with coronary artery disease — myocardial infarction. Beta blocker therapy should always be initiated and titrated under medical supervision, particularly in heart failure patients.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.